Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis
Regulatory differences between the US and Europe limit rare disease drug approval, revealing policy barriers that affect patient access.
Analysis of 344 rare disease drug approvals (2011-2020) found major US-EU divergence in orphan designation, with only 40.4% of EU approvals receiving orphan status vs 97.7% in the US. Regulatory divergence was particularly marked for cancer subsets and pediatric disease subsets, with policy implications for market exclusivity incentives that may affect rare disease drug access in Europe.
What the study was
- Study design
- Cross-sectional study (regulatory database analysis)
- Population
- 344 rare disease drug approvals in US and EU from 2011-2020 (FDA and EMA databases)
- Sample size
- 344
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Clin Pharmacol Ther
Why it surfaced
Policy analysis quantifying US-EU orphan drug designation divergence; directly relevant to rare disease access inequality and incentive structure reform.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.